Please use this identifier to cite or link to this item: https://ninho.inca.gov.br/jspui/handle/123456789/4255
Full metadata record
DC FieldValueLanguage
dc.contributor.authorInstituto Nacional de Câncer José Alencar Gomes da Silva-
dc.contributor.authorINCA-
dc.contributor.authorInstituto Nacional de Câncer (Brasil)-
dc.contributor.authorSistema Único de Saúde (Brasil)-
dc.contributor.authorBrasil. Ministério da Saúde-
dc.date.accessioned2021-10-14T15:43:18Z-
dc.date.available2021-10-14T15:43:18Z-
dc.date.issued2021-09-
dc.identifier.urihttp://sr-vmlxaph03:8080/jspui/handle/123456789/4255-
dc.description1 p.-
dc.language.isoPortuguêspt_BR
dc.publisherINCApt_BR
dc.relation.ispartofseriesAno V, n. 52.-
dc.subjectNeoplasiaspt_BR
dc.subjectAntineoplásicospt_BR
dc.subjectNeoplasmspt_BR
dc.subjectAntineoplastic Agents-
dc.titleCapacidade funcional e tratamento antineoplásicopt_BR
dc.TypeRevistas/Boletinspt_BR
Appears in Collections:Informe SUS - ONCO 2021

Files in This Item:
File Description SizeFormat 
Setembro_2021.pdf487.77 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.